Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000190034 | SCV000243707 | pathogenic | not provided | 2014-11-20 | criteria provided, single submitter | clinical testing | p.Gln1525Ter (CAG>TAG): c.4573 C>T in exon 36 of the TSC2 gene (NM_000548.3)The Q1525X nonsense mutation in the TSC2 gene has been reported previously in association with tuberous sclerosis (Langkau et al., 2002; TSC2 LOVD). This mutation is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The variant is found in EPILEPSY panel(s). |
Invitae | RCV001042432 | SCV001206111 | pathogenic | Tuberous sclerosis 2 | 2023-07-17 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 49306). This premature translational stop signal has been observed in individual(s) with tuberous sclerosis (PMID: 12111193). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gln1525*) in the TSC2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TSC2 are known to be pathogenic (PMID: 10205261, 17304050). |
Genome- |
RCV001042432 | SCV002041001 | pathogenic | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Tuberous sclerosis database |
RCV000042565 | SCV000066359 | not provided | Tuberous sclerosis syndrome | no assertion provided | curation | ||
Division of Genomic Medicine, |
RCV001042432 | SCV001364439 | pathogenic | Tuberous sclerosis 2 | 2020-06-11 | no assertion criteria provided | clinical testing |